NDA, MAA Remain Key Focal Points for Celator Pharma (CPXX) Moving Forward; Roth Affirms at 'Buy'

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. MU
6. FDX
7. IBM
8. PRIM
9. PFE
10. AWK

Go back to NDA, MAA Remain Key Focal Points for Celator Pharma (CPXX) Moving Forward; Roth Affirms at 'Buy'

Celator Pharmaceuticals (CPXX) Misses Q4 EPS by 1c

March 21, 2016 8:21 AM EDT

Celator Pharmaceuticals (NASDAQ: CPXX) reported Q4 EPS of ($0.13), $0.01 worse than the analyst estimate of ($0.12).

The following are expected milestones for VYXEOS:

3Q 2016 New Drug Application (NDA) submission1Q 2017 Marketing Authorization Application (MAA) submissionMid-2017 Prescription Drug User Fee Act (PDUFA)... More